Brief: BB Biotech Q3 Net Loss At CHF 157 Mln

Bb Biotech

25/10/2024 06:05

Oct 25 (Reuters) - BB BIOTECH AG  BION.S :
    * STRATEGIC REALLOCATION OF PORTFOLIO ASSETS PROGRESSING
    * CLOSED Q3 WITH A NET LOSS OF CHF 157 MN
    * POSITIVE RESULTS FROM A PHASE I/II STUDY OF ION582
(ANGELMAN
SYNDROME)
    * AT NINE-MONTH MARK, SHOWED NET PROFIT OF CHF 16 MN
COMPARED TO A
NET LOSS OF CHF 316 MN IN FIRST NINE MONTHS OF 2023
    * HIGH LEVEL OF INVESTMENT OF 112.3% REFLECTS INVESTMENT
MANAGEMENT TEAM'S CONFIDENCE REGARDING FUTURE DEVELOPMENTS
    * AS Q3 CONCLUDED, INVESTMENT LEVEL DECREASED BUT REMAINED
NEAR
UPPER LIMIT OF TARGET RANGE AT 112.3%
    * Q3 SHARES SHOWED A RETURN OF -9.2.% IN CHF AND -6.7% IN
EUR

Source text for Eikon:  ID:nEQ3V2rzFa 
Further company coverage:  BION.S 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 769 66 00;))